1 Balkwill, F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13, 135–141.
2 Locksley, RM, Killeen, N & Lenardo, MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501.
3 MacEwan, DJ (2002) TNF ligands and receptors – a matter of life and death. Br J Pharmacol 135, 855–875.
4 Ferrara, N, Gerber, HP & LeCouter, J (2003) The biology of VEGF and its receptors. Nat Med 9, 669–676.
5 Larcher, F, Murillas, R, Bolontrade, M, et al. (1998) VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17, 303–311.
6 Borchers, AT, Keen, CL, Hannum, SM, et al. (2000) Cocoa and chocolate: composition, bioavailability, and health implications. J Med Food 3, 77–105.
7 Corti, R, Flammer, AJ, Hollenberg, NK, et al. (2009) Cocoa and cardiovascular health. Circulation 119, 1433–1441.
8 Serafini, M, Bugianesi, R, Maiani, G, et al. (2003) Plasma antioxidants from chocolate. Nature 424, 1013.
9 McShea, A, Ramiro-Puig, E, Munro, SB, et al. (2008) Clinical benefit and preservation of flavonols in dark chocolate manufacturing. Nutr Rev 66, 630–641.
10 Lee, KW, Kim, YJ, Lee, HJ, et al. (2003) Cocoa has more phenolic phytochemicals and a higher antioxidant capacity than teas and red wine. J Agric Food Chem 51, 7292–7295.
11 Lee, KW, Hwang, ES, Joo, KN, et al. (2005) Extraction and chromatographic separation of anticarcinogenic fractions from cacao bean husk. BioFactors 23, 141–150.
12 Lee, KW, Kundu, JK, Sue, OK, et al. (2006) Cocoa polyphenols inhibit phorbol ester-induced superoxide anion formation in cultured HL-60 cells and expression of cyclooxygenase-2 and activation of NF-κB and MAPKs in mouse skin in vivo. J Nutr 136, 1150–1155.
13 Lee, KW, Kang, NJ, Oak, MH, et al. (2008) Cocoa procyanidins inhibit expression and activation of MMP-2 in vascular smooth muscle cells by direct inhibition of MEK and MT1-MMP activities. Cardiovasc Res 79, 34–41.
14 Kang, NJ, Lee, KW, Lee, DE, et al. (2008) Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase kinase. J Biol Chem 283, 20664–20673.
15 Kwon, JY, Lee, KW, Kim, JE, et al. (2009) Delphinidin suppresses ultraviolet B-induced cyclooxygenases-2 expression through inhibition of MAPKK4 and PI-3 kinase. Carcinogenesis 30, 1932–1940.
16 Lee, KW, Kang, NJ, Rogozin, EA, et al. (2007) Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 28, 1918–1927.
17 Nomura, M, Kaji, A, He, Z, et al. (2001) Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem 276, 46624–46631.
18 Lee, KW, Kang, NJ, Oak, M-H, et al. (2008) Cocoa procyanidins inhibit expression and activation of MMP-2 in vascular smooth muscle cells by direct inhibition of MEK and MT1-MMP activities. Cardiovasc Res 79, 34–41.
19 Kang, NJ, Lee, KW, Lee, DE, et al. (2008) Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase kinase. J Biol Chem 283, 20664–20673.
20 Yan, Y, Li, J, Ouyang, W, et al. (2006) NFAT3 is specifically required for TNF-α-induced cyclooxygenase-2 (COX-2) expression and transformation of Cl41 cells. J Cell Sci 119, 2985–2994.
21 Arnott, CH, Scott, KA, Moore, RJ, et al. (2004) Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene 23, 1902–1910.
22 Moore, RJ, Owens, DM, Stamp, G, et al. (1999) Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 5, 828–831.
23 Scott, KA, Moore, RJ, Arnott, CH, et al. (2003) An anti-tumor necrosis factor-α antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2, 445–451.
24 Kim, JE, Kwon, JY, Seo, SK, et al. (2010) Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. Biochem Pharmacol 79, 1473–1482.
25 Choi, KH, Kim, J-E, Song, NR, et al. (2010) Phosphoinositide-3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res 85, 836–844.
26 Taubert, D, Roesen, R, Lehmann, C, et al. (2007) Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA 298, 49–60.
27 Spadafranca, A, Martinez Conesa, C, Sirini, S, et al. (2010) Effect of dark chocolate on plasma epicatechin levels, DNA resistance to oxidative stress and total antioxidant activity in healthy subjects. Br J Nutr 103, 1008–1014.
28 Schroeter, H, Heiss, C, Balzer, J, et al. (2006) ( − )-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci U S A 103, 1024–1029.
29 Yamagishi, M, Natsume, M, Osakabe, N, et al. (2002) Effects of cacao liquor proanthocyanidins on PhIP-induced mutagenesis in vitro, and in vivo mammary and pancreatic tumorigenesis in female Sprague–Dawley rats. Cancer Lett 185, 123–130.
30 Yamagishi, M, Natsume, M, Osakabe, N, et al. (2003) Chemoprevention of lung carcinogenesis by cacao liquor proanthocyanidins in a male rat multi-organ carcinogenesis model. Cancer Lett 191, 49–57.
31 Osakabe, N, Yamagishi, M, Natsume, M, et al. (2000) Antioxidative polyphenolic substances in cacao liquor. ACS Symp Ser 754, 88–101.
32 Szlosarek, P, Charles, KA & Balkwill, FR (2006) Tumour necrosis factor-α as a tumour promoter. Eur J Cancer 42, 745–750.
33 Jośko, J & Mazurek, M (2004) Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10, RA89–RA98.
34 Shibata, A, Nagaya, T, Imai, T, et al. (2002) Inhibition of NF-κB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 73, 237–243.
35 Lee, CC, Chen, SC, Tsai, SC, et al. (2006) Hyperbaric oxygen induces VEGF expression through ERK, JNK and c-Jun/AP-1 activation in human umbilical vein endothelial cells. J Biomed Sci 13, 143–156.
36 Ouyang, W, Li, J, Shi, X, et al. (2005) Essential role of PI-3K, ERKs and calcium signal pathways in nickel-induced VEGF expression. Mol Cell Biochem 279, 35–43.
37 Sebolt-Leopold, JS & English, JM (2006) Mechanisms of drug inhibition of signalling molecules. Nature 441, 457–462.
38 Walker, EH, Pacold, ME, Perisic, O, et al. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6, 909–919.
39 Cortes, JR, Perez, GM, Rivas, MD, et al. (2007) Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol 179, 3881–3887.
40 Kang, NJ, Lee, KW, Rogozin, EA, et al. (2007) Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem 282, 32856–32866.
41 Raynaud, FI, Eccles, S, Clarke, PA, et al. (2007) Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67, 5840–5850.
42 Kim, JE, Kwon, JY, Lee, DE, et al. (2009) MKK4 is a novel target for the inhibition of tumor necrosis factor-α-induced vascular endothelial growth factor expression by myricetin. Biochem Pharmacol 77, 412–421.
43 Vogt, PK & Kang, S (2006) Kinase inhibitors: vice becomes virtue. Cancer Cell 9, 327–328.